Myriad Genetics, Inc. Financials

Market Capitalization $1.16 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-4.03
Forward PE	85.07
Price to Sales TTM	$1.41
Price to Book MRQ	$1.59
Enterprise to Revenue	1.46
Enterprise to EBITDA	-35.54

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-14.09%
Operating Margin	-8.35%
Return on Assets TTM	-5.35%
Return on Equity TTM	-16.40%

Income Statement

Revenue TTM	$823,600,000
Revenue per Share TTM	$9.21
Quarterly Revenue Growth	11.20%
Gross Profit TTM	$569,500,032
EBITDA	$-33,900,000
Net Income to Common TTM	$-116,000,000
Diluted EPS TTM	$-1.28
Quarterly Earnings Growth YoY	11.15%

Balance Sheet

Total Cash MRQ	$99,900,000
Total Cash per Share MRQ	$1.10
Total Debt MRQ	$
Total Debt to Equity MRQ	19.56
Current Ratio MRQ	1.90
Book Value per Share MRQ	$8.04

Cash Flow

Operating Cash Flow TTM	$-70,000,000
Levered Free Cash Flow TTM	$-52,900,000

MYGN Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	91,035,200
Float Shares	83,483,858
Avg 10 Volume	1,000,040
Avg 30 Volume	None
Shares Short	4,782,565
Short Ratio	4.47
Short % of Shares	7.35%
% Held by Insiders	2.01%
% Held by Institutions	102.58%

Stock Price Summary

Beta	1.94
Fifty Two Week Low	$12.04
Fifty Two Week High	$29.30
Fifty Two Week Change	-77.22%
Day 50 MA	$14.61
Day 200 MA	$21.91

Dividends and Splits

Forward Annual Dividend Rate	$21.00
Forward Annual Dividend Yield	163.81%
Trailing Annual Dividend Rate	$3.50
Trailing Annual Dividend Yield	27.30%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2009-07-01
Last Split Factor
Last Split Date	2009-03-26